Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,312 public trials 521 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Completed

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

NCT04646005

Conditions
Adenocarcinoma, Carcinoma, Cervical Cancer, +21 more
Locations
  • Arizona Oncology Associates Tucson, Arizona, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • Regeneron Research Site Orange, California, United States
  • Universitair Ziekenhuis Gent Ghent, East Flanders, Belgium
View all 26 locations
View Trial Details
Completed

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

NCT04191616

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Rocky Mountain Cancer Centers Denver Midtown Denver, Colorado, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Affiliated Oncologists, LLC Chicago Ridge, Illinois, United States
View all 46 locations
View Trial Details
Completed

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

NCT03581786

Conditions
Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, +2 more
Locations
  • Cancer Hospital, Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Fujian Provincial Cancer Hospital Fuzhou, Fujian, China
  • Sun Yat-Sen University Cancer Center Guangzhou, Guangdong, China
View all 32 locations
View Trial Details
Completed

Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)

NCT06648512

Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse, Disease Attributes, +10 more
Locations
  • Medizinische Universität Graz Graz, Austria
  • FHRB (Finnish Hematology Registry and Clinical Biobank) Vantaa, Finland
  • Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie und Onkologie Berlin, Germany
View Trial Details
Completed

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

NCT02998476

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Arizona Oncology Associates, PC - HAL Tempe, Arizona, United States
  • Sutter Gould Medical Foundation Modesto, California, United States
View all 70 locations
View Trial Details

Related conditions